Evidence map›Paper›PMID 39285908›Full record

ReviewThe journal of venomous animals and toxins including tropical diseases2024

Snake venom bioprospecting as an approach to finding potential anti-glioblastoma molecules.

Javier Orozco-Mera, Alejandro Montoya-Gómez, Daiana Silva Lopes, Eliécer Jiménez-Charris

Abstract readReview
In one paragraph

Review in The journal of venomous animals and toxins including tropical diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Javier Orozco-MeraGrupo de Nutrición, Facultad de Salud, Universidad del Valle, Cali, Colombia.ORCID https://orcid.org/0000-0002-4293-4659
Alejandro Montoya-GómezGrupo de Nutrición, Facultad de Salud, Universidad del Valle, Cali, Colombia.ORCID https://orcid.org/0000-0002-0494-4207
Daiana Silva LopesMultidisciplinary Institute in Health, Federal University of Bahia (UFBA), Vitória da Conquista, BA, Brazil.ORCID https://orcid.org/0000-0002-2462-4163
Eliécer Jiménez-CharrisGrupo de Nutrición, Facultad de Salud, Universidad del Valle, Cali, Colombia.ORCID https://orcid.org/0000-0001-6043-1521

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GB) is the most common type of malignant tumor of the central nervous system, responsible for significant morbidity and with a 5-year overall relative survival of only 6.8%. Without advances in treatment in the last twenty years, the standard of care continues to be maximum safe resection, Temozolomide (TMZ), and radiotherapy. Many new trials are ongoing, and despite showing increased progression-free survival, these trials did not improve overall survival. They did not consider the adverse effects of these therapies. Therefore, an increasing number of bioprospecting studies have used snake venom molecules to search for new strategies to attack GB selectively without producing side effects. The present review aims to describe GB characteristics and current and new approaches for treatment considering their side effects. Besides, we focused on the antitumoral activity of snake venom proteins from the Viperidae family against GB, exploring the potential for drug design based on

Indexed as

BioprospectingDrug discoveryGlioblastomaSnake venomTherapeuticsViperidae

Identifiers

PMID39285908
PMCPMC11404105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.